Ratings by Guggenheim (Debjit Chattopadhyay)

Date CompanySymbol Type Rating
(Past)
PT
(Past)
Start $
(End $)
% Chg. Details
6/27/2022 Alnylam Pharmaceuticals ALNY Downgrade Neutral
(Buy)
147.50
(145.83)
-1.13% Details
5/2/2022 uniQure BV QURE Maintain Buy
(N/A)
 
 
  Details
4/5/2022 Taysha Gene Therapies TSHA Maintain Buy
(N/A)
 
 
  Details
3/1/2022 Ionis Pharmaceuticals IONS New Coverage Buy
(N/A)
33.38
(37.57)
12.55% Details
3/1/2022 Beam Therapeutics Inc BEAM Maintain Buy
(N/A)
 
 
  Details
2/25/2022 uniQure BV QURE Maintain Buy
(N/A)
 
 
  Details
2/24/2022 Intellia Therapeutics NTLA Maintain Buy
(N/A)
 
 
  Details
2/3/2022 Alnylam Pharmaceuticals ALNY Upgrade Buy
(Neutral)
145.26
(145.83)
0.39% Details
1/5/2022 Beam Therapeutics Inc BEAM New Coverage Buy
(N/A)
78.31
(38.58)
-50.73% Details
12/16/2021 Taysha Gene Therapies TSHA New Coverage Buy
(N/A)
14.24
(3.70)
-74.02% Details
12/1/2021 Vertex VRTX Maintain Buy
(N/A)
 
 
  Details
10/5/2021 Intellia Therapeutics NTLA New Coverage
(N/A)
126.78
(52.39)
-58.68% Details
7/15/2021 Ultragenyx Pharma RARE New Coverage Neutral
(N/A)
84.74
(60.00)
-29.2% Details
5/6/2021 Freeline FRLN New Coverage Buy
(N/A)
11.25
(0.87)
-92.27% Details
1/7/2021 Sangamo BioSciences SGMO New Coverage Neutral
(N/A)
16.01
(4.20)
-73.77% Details
1/6/2021 uniQure BV QURE Upgrade Buy
(Neutral)
37.77
(18.52)
-50.97% Details